Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614612 · ClinicalTrials.gov registry record · Phase 1
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02614612 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 31 participants.
The verdict
NCT02614612, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).
Interventions
- DRUG Itacitinib (200 mg)
- DRUG Itacitinib (300 mg)
- DRUG prednisone or methylprednisolone (corticosteroids)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614612
The ClinicalTrials.gov registry entry for NCT02614612 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itacitinib (200 mg) is the first listed.
NCT02614612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614612 about?
NCT02614612 is a clinical study titled "Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD". To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).
What is the current status of trial NCT02614612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-12. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02614612?
The interventions under investigation include: Itacitinib (200 mg) (DRUG), Itacitinib (300 mg) (DRUG), prednisone or methylprednisolone (corticosteroids) (DRUG).
Who is sponsoring clinical trial NCT02614612?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.